Document ID: chunk:federal_register_of_legislation:F2025C00124:reg:6:p3
Version: federal_register_of_legislation:F2025C00124
Segment Type: reg
Provision Reference: reg 6 (pt 3/4)
Character Range: 14157–17611

meaning given by section 32.
EFC patient has the meaning given by subsection 8(7).
eligible patient has the meaning given by section 8.
General statement for drugs for the treatment of hepatitis C has the same meaning as in the Listing Instrument.
highly specialised drug means a listed drug mentioned in Schedule 1.
hospital authority has the same meaning as in Part VII of the Act.
HSD hospital authority means a hospital authority for which:
 (a) an approval under section 94 of the Act, as modified by section 10 of this instrument, is in force; or
 (b) an approval mentioned in section 38 of this instrument is in force.
HSD pharmaceutical benefit means a pharmaceutical benefit mentioned in Schedule 1.
listed drug has the same meaning as in Part VII of the Act.

Listing Instrument means the National Health (Listing of Pharmaceutical Benefits) Instrument 2024 (PB 26 of 2024).

medication chart prescription has the same meaning as in the Regulations.
medication for the treatment of hepatitis B means any of the following:
 (a) adefovir;
 (b) entecavir;
 (c) lamivudine;
 (d) tenofovir.
medication for the treatment of hepatitis C means medication mentioned in the table in clause 3 of the General statement for drugs for the treatment of hepatitis C.
medication for the treatment of HIV or AIDS means any of the following:
            (a) abacavir;
            (b) abacavir with lamivudine;
            (c) atazanavir;
            (d) atazanavir with cobicistat;
            (e) azithromycin;
            (f) bictegravir with emtricitabine with tenofovir alafenamide;
            (g) cabotegravir;
            (h) cabotegravir and rilpivirine;
            (i) darunavir;
            (j) darunavir with cobicistat;
            (k) darunavir with cobicistat, emtricitabine and tenofovir alafenamide;
            (l) dolutegravir;
            (m) dolutegravir with abacavir and lamivudine;
            (n) dolutegravir with lamivudine;
            (o) dolutegravir with rilpivirine;
            (p) doxorubicin ‑ pegylated liposomal;
            (q) emtricitabine with rilpivirine with tenofovir alafenamide;
            (r) emtricitabine with tenofovir alafenamide;
            (s) etravirine;
            (t) ganciclovir;
            (u) lamivudine;
            (v) lamivudine with zidovudine;
            (w) lopinavir with ritonavir;
            (x) maraviroc;
            (y) nevirapine;
            (z) raltegravir;
            (aa) rifabutin;
            (bb) rilpivirine;
            (cc) ritonavir;
            (dd) tenofovir;
            (ee) tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat;
            (ff) tenofovir with emtricitabine;
            (gg) tenofovir with emtricitabine and efavirenz;
            (hh) valganciclovir;
            (ii) zidovudine.
medication for the treatment of opioid dependence means any of the following:
 (a) buprenorphine;
 (b) buprenorphine with naloxone;
 (c) methadone.
medication for the treatment of schizophrenia means clozapine.
ODT pharmaceutical benefit means an HSD pharmaceutical benefit that has a drug that is a medication for the treatment of opioid dependence.
pack quantity has the same meaning as in Part VII of the Act.
pharmaceutical benefit has the same meaning as in Part VII of the Act.
pharmaceutical item has the same meaning as in Part VII of the Act.
proportional ex‑manufacturer price of a listed brand of a pharmaceutical item has the same meaning as